Sanofi (SNYNF,SNY) reported fourth quarter net income from continuing operations of 880 million euros compared to a loss of 119 million euros, prior year. Basic earnings per share from continuing operations was 0.69 euros compared to a loss of 0.09 euros. Business net income declined to 1.64 billion euros from 1.93 billion euros, prior year. Business earnings per share was 1.31 euros, decreased by 14.9% or down 11.0% at CER. Net sales were 10.56 billion euros, increased by 9.1% or 10.3% at CER.
In fiscal 2024, business earnings per share was 7.12 euros, decreased by 1.8% , or up 4.1% at CER. Net sales were 41.08 billion euros, and increased by 8.6% or 11.3% at CER. The Board of Directors proposed a dividend of 3.92 euros for 2024.
Paul Hudson, CEO, said: "We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. We exceeded our business EPS guidance. As we enter 2025, we expect continued, solid growth in sales and a strong rebound in earnings. We are also confident in the mid to long-term growth prospects of Sanofi, supported by ongoing launches, Dupixent, and expected future launches from our pipeline."
In 2025, the company expects sales to grow by a mid-to-high single-digit percentage at CER. Sanofi confirmed the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER, before share buyback.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.